Jun 13
J&J multiple myeloma drug Talvey cuts mortality risk by up to 53% in late-stage trial
Synthesized from 6 sources
Sources (6)
Bias Scale:
LeftCenterRight
Seeking AlphaJun 13, 2026, 2:14 PM
Sanofi type 1 diabetes therapy Tzield approved in U.S. for stage 3 of the diseaseSeeking AlphaJun 13, 2026, 12:54 PM
J&J multiple myeloma drug Talvey cuts mortality risk by up to 53% in late-stage trialCNBCJun 13, 2026, 12:00 PM
Drugmakers race to find a place in the next wave of obesity drugsSeeking AlphaJun 13, 2026, 11:00 AM
KFC vibes: Yum! Brands tests a new concept for Colonel SandersWall Street JournalJun 13, 2026, 2:00 AM
The 70-Year Marriage Between McDonald’s and Coke Has Some IssuesReutersJun 13, 2026, 12:24 AM
First Brands moves ahead with liquidation planComments
No comments yet. Be the first!